Ambry Genetics was the first commercial laboratory to begin offering clinical diagnostic exome sequencing testing in 2011 3, which may bring new hope to thousands of patients and families searching ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient ... delayed or missed without the laboratory-initiated Patient ...

Genetic counseling (GC) in the era of next generation sequencing (NGS) to diagnose microsatellite instability (MSI) and deficient mismatch repair (dMMR) expression in colorectal cancer (CRC). This is ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program ... that may have been delayed or missed without the ...

In its latest earnings release, Tempus AI, Inc. (NASDAQ:TEM) said that it is targeting $1.25 billion in revenues for the consolidated Tempus and Ambry Genetics for full-year 2025, which would ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The company reports a first-quarter adjusted loss of 24 cents per share, beating analyst ...

Patients with stages I to III breast cancer who were seen at a single cancer center between 2010 and 2012, and who agreed to participate in research DNA banking, were included (N = 488). Personal and ...

Multiple bidders are likely to submit offers for the DNA data bank and other assets of bankrupt genetic-testing firm 23andMe, according to a lawyer for the company. Although 23andMe was unable to ...

Researchers work in a mobile Fire-Eye laboratory in Beijing in June 2020. The labs can identify coronavirus infections, as well as decipher and analyze human DNA. (Fu Tian/China News Service/Getty ...

⁸, ⁹ This challenge is compounded by the nationwide shortage of genetic professionals.¹⁰ Digital Solutions Make Universal Risk Assessment Possible The Ambry CARE Program® (CARE ...